

REMARKS**New claims**

New claims 21 and 22 depend on claim 10 (currently amended). Claim 23 rewrites claim 19 (now canceled) in independent form; claim 19 was not the subject of any rejections in the Office action. Claims 24 and 25 depend on claim 23, and recite limitations identical to those of original claims 11 and 12.

The enablement rejection

The examiner rejected claims 3 and 10-15 under 35 U.S.C. § 112, first paragraph, arguing that the specification does not enable a method of preventing death or degeneration of neurons. The applicants disagree that the rejection is proper. Nonetheless, to advance prosecution, the applicants have canceled claim 3 and amended claim 10 such that it no longer recites the limitation “prevent,” thus mooting the rejection. The applicants respectfully request that the examiner withdraw it.

The obviousness rejection

The examiner rejected claims 1-3, 5-8, 16-18, and 20 under 35 U.S.C. § 103(a), arguing that the claims are obvious in view of the Arnsten, O’Rourke, and Allergan references. The applicants have canceled the rejected claims, thus mooting the rejection.

The undersigned authorizes the Director to charge any fees required or necessary for the filing, processing or entering of this paper or any of the papers transmitted with it, and to refund any overpayment, to deposit account 01-0885.

Respectfully submitted,

/Joel B. German/

Joel B. German, Esq.
Attorney of Record
Registration No. 48,676

Please direct all correspondence and inquiries to:

Joel B. German, Esq.
Allergan, Inc.
2525 Dupont Drive, T2-7H
Irvine, CA 92612
Tel: (714) 246- 4920
Fax: (714) 246-4249